Test an oncolytic virus treatment for solid tumors
Part of Cancer, Digestive system clinical trials.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid tumor that cannot be removed or has come back/spread
- You’ve either already tried standard treatment and it stopped working, or there is no standard option for your cancer
- Your doctors can measure at least one tumor spot on scans to track response
- You feel well enough for treatment (ECOG 0–1) and are expected to live more than 3 months
- At least one tumor can be reached with an injection directly into the tumor
- You have adequate blood/organ function and can follow study instructions and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests OH2 given as an injection directly into certain tumors (intratumoral injection) in people with advanced melanoma or several other solid cancers that are hard to remove. It aims to see whether the treatment is safe and if it can help control cancer by reaching the tumor more directly.
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
This Phase 1 study tests STI-1386, an oncolytic (tumor-fighting) virus, for solid tumors that have relapsed or do not respond to treatment. It mainly checks safety, and also looks for early signs of how well it may work.
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
This trial tests an investigational drug called IDOV-Immune for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.